CNS Drugs

, Volume 26, Issue 6, pp 491–508

Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia

What have Real-World Trials Taught Us?
Review Article

Abstract

Real-world, effectiveness studies add an important new dimension to the evaluation of the benefits of individual antipsychotics. Efficacy studies have already shown the unique effectiveness of clozapine, and suggested improved outcomes for olanzapine compared with some atypical antipsychotics and a reduced tendency to produce acute and chronic movement disorders for atypical compared with typical drugs. Recent effectiveness studies largely confirm these prior observations. The CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), CUtLASS (Cost Utility of the Latest Anti-psychotic Drugs in Schizophrenia Study) and SOHO (Schizophrenia Outpatient Health Outcomes) programmes confirmed the superiority of clozapine over other antipsychotics; CATIE and SOHO also confirmed olanzapine as probably the second most effective antipsychotic. Effectiveness studies have confirmed the high incidence of adverse metabolic effects with clozapine, olanzapine and (with less certainty) quetiapine but the ZODIAC (Ziprasi-done Observational Study of Cardiac Outcomes) study found no excess cardiovascular events or deaths for olanzapine compared with ziprasidone. Prior observations on reduced frequency of movement disorders for second-generation versus first-generation antipsychotics were also largely (but not uniformly) supported.

Overall, recent real-world studies have done much to confirm prior ob-servations from efficacy-based randomized, controlled trials.

References

  1. 1.
    Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29(1): 15–31PubMedCrossRefGoogle Scholar
  2. 2.
    Strom BL, Faich GA, Reynolds RF, et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 2008; 69(1): 114–21PubMedCrossRefGoogle Scholar
  3. 3.
    Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163(4): 611–22PubMedCrossRefGoogle Scholar
  4. 4.
    Lieberman JA, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRefGoogle Scholar
  5. 5.
    McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163(4): 600–10PubMedCrossRefGoogle Scholar
  6. 6.
    Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107(1): 1–12PubMedCrossRefGoogle Scholar
  7. 7.
    Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193(4): 279–88PubMedCrossRefGoogle Scholar
  8. 8.
    Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101(1–3): 273–86PubMedCrossRefGoogle Scholar
  9. 9.
    Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163(12): 2090–5PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 2009; 107(1): 22–9PubMedCrossRefGoogle Scholar
  11. 11.
    Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163(12): 2080–9PubMedCrossRefGoogle Scholar
  12. 12.
    Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63(10): 1079–87PubMedCrossRefGoogle Scholar
  13. 13.
    Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191: 14–22PubMedCrossRefGoogle Scholar
  14. 14.
    Davies LM, Barnes TR, Jones PB, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 2008; 11(4): 549–62PubMedCrossRefGoogle Scholar
  15. 15.
    Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32(4): 715–23PubMedCrossRefGoogle Scholar
  16. 16.
    Heinrichs DW, Hanlon TE, Carpenter WT, et al. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10(3): 388–98PubMedCrossRefGoogle Scholar
  17. 17.
    Kind P. The EuroQoL instrument: an indicator of health related quality of life and pharmacoeconomics on clinical trials. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. New York: Lippincott-Raven, 1996: 191–202Google Scholar
  18. 18.
    Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33(6): 766–71PubMedCrossRefGoogle Scholar
  19. 19.
    Haro JM, Edgell ET, Frewer P, et al. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand Suppl 2003; (416): 7–15PubMedCrossRefGoogle Scholar
  20. 20.
    Guy W. The Clinical Global Impressions Scale. In: Guy W, editor. ECDEU assessment manual for psychopharma-cology [rev. ed.]. Rockville (MD): National Institute of Mental Health, 1976: 157–69Google Scholar
  21. 21.
    Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111(3): 220–31PubMedCrossRefGoogle Scholar
  22. 22.
    Dossenbach M, Rango-Davila C, Silva IH, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005; 66(8): 1021–30PubMedCrossRefGoogle Scholar
  23. 23.
    Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; (416): 16–23PubMedCrossRefGoogle Scholar
  24. 24.
    Haro JM, Novick D, Belger M, et al. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 2006 Jan; 21(1): 41–7PubMedCrossRefGoogle Scholar
  25. 25.
    Novick D, Haro JM, Suarez D, et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl) 2007; 191(4): 1015–22CrossRefGoogle Scholar
  26. 26.
    Haro JM, Novick D, Suarez D, et al. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res 2009; 43(3): 265–73PubMedCrossRefGoogle Scholar
  27. 27.
    Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26(6): 571–8PubMedCrossRefGoogle Scholar
  28. 28.
    Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009; 12(4): 536–43PubMedCrossRefGoogle Scholar
  29. 29.
    Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005; 66(9): 1130–3PubMedCrossRefGoogle Scholar
  30. 30.
    Tenback DE, van Harten PN, Slooff CJ, et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Am J Psychiatry 2006; 163(8): 1438–40PubMedCrossRefGoogle Scholar
  31. 31.
    Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009; 19(8): 542–50PubMedCrossRefGoogle Scholar
  32. 32.
    Bitter I, Basson BR, Dossenbach MR. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. Int Clin Psychopharmacol 2005; 20(1): 19–21PubMedCrossRefGoogle Scholar
  33. 33.
    Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006; 21(4): 251–8PubMedCrossRefGoogle Scholar
  34. 34.
    Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011; 168(2): 193–201PubMedCrossRefGoogle Scholar
  35. 35.
    Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96PubMedCrossRefGoogle Scholar
  36. 36.
    Leucht S, Komossa Rummel-Kluge C, et al. A metaanalysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152–63PubMedCrossRefGoogle Scholar
  37. 37.
    Allison D, Mentore J, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96PubMedGoogle Scholar
  38. 38.
    Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31–41PubMedCrossRefGoogle Scholar
  39. 39.
    Beasley C, Dellva M, Tamura R. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30PubMedCrossRefGoogle Scholar
  40. 40.
    McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189:433–40PubMedCrossRefGoogle Scholar
  41. 41.
    Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009; 70(4): 572–81PubMedCrossRefGoogle Scholar
  42. 42.
    Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007; 68 Suppl. 1:5–11PubMedGoogle Scholar
  43. 43.
    Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 Suppl. 1: 20–7PubMedGoogle Scholar
  44. 44.
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13(1): 177–83PubMedCrossRefGoogle Scholar
  45. 45.
    Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009; 23(8): 649–59PubMedGoogle Scholar
  46. 46.
    Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006; 11(7 Suppl. 7): 25–31PubMedGoogle Scholar
  47. 47.
    Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161(3): 414–25PubMedCrossRefGoogle Scholar
  48. 48.
    Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64(9): 1075–80PubMedCrossRefGoogle Scholar
  49. 49.
    Kraemer HC, Glick ID, Klein DF. Clinical trials design lessons from the CATIE study. Am J Psychiatry 2009; 166(11): 1222–8PubMedCrossRefGoogle Scholar
  50. 50.
    Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry 2006; 67(5): 831–2PubMedCrossRefGoogle Scholar
  51. 51.
    Lieberman JA. Comparative effectiveness of antipsychotic drugs: a commentary on Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006; 63(10): 1069–72PubMedCrossRefGoogle Scholar
  52. 52.
    Sparshatt A, Taylor D, Patel MX, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 2011; 72(8): 1108–23PubMedCrossRefGoogle Scholar
  53. 53.
    Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008; 22(1): 49–68PubMedCrossRefGoogle Scholar
  54. 54.
    Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009; 29(3): 278–83PubMedCrossRefGoogle Scholar
  55. 55.
    Soares BG, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database Syst Rev 2000; (2): CD001162PubMedGoogle Scholar
  56. 56.
    Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharma-cology (Berl) 2001; 155(3): 230–3CrossRefGoogle Scholar
  57. 57.
    Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008; 59(5): 523–5PubMedCrossRefGoogle Scholar
  58. 58.
    Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010; 55(3): 117–25PubMedGoogle Scholar
  59. 59.
    Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72(11): 1439–44PubMedCrossRefGoogle Scholar
  60. 60.
    Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv 2008; 59(5): 500–6PubMedCrossRefGoogle Scholar
  61. 61.
    Tenback DE, van Harten PN, Slooff CJ, et al. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006; 31(8): 1832–7PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Pharmacy DepartmentSouth London and Maudsley NHS Foundation TrustLondonUK
  2. 2.Institute of Pharmaceutical ScienceKing’s CollegeLondonUK

Personalised recommendations